ArticleFrontiers in oncology2025
Prediction of histopathological grade in gastric cancer using dual energy CT-derived synthetic extracellular volume fraction.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the relationship between the synthetic extracellular volume (ECV) fraction and the hematocrit (HCT)-based ECV fraction in gastric cancer patients and to evaluate its potential utility in predicting the pathological grade of gastric cancer. Methods: Data from the derivation cohort consisting of 142 patients who underwent nonenhanced abdominal CT examination were collected, and the CT values of the abdominal aorta (CTA) and inferior vena cava (CTV) were measured separately. Using linear regression between CT attenuations and conventional hematocrit (HCT Results: Derived formulas: Conclusions: Synthetic ECV performs comparably to conventional ECV and predicts gastric cancer pathological grading effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.